Drug Profile
Research programme: anticancer therapeutics - Thallion Pharmaceuticals/ImClone Systems
Latest Information Update: 14 Apr 2009
Price :
$50
*
At a glance
- Originator Caprion Pharmaceuticals; ImClone Systems
- Developer ImClone Systems; Thallion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Apr 2009 No development reported - Preclinical for Cancer in Canada (unspecified route)
- 14 Apr 2009 No development reported - Preclinical for Cancer in USA (unspecified route)
- 24 Nov 2008 ImClone Systems has been acquired by Eli Lilly and Company